Ambagon Therapeutics Launches With $85 Million Series A to A

Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target class Initial discovery pipeline focused on high-value

Related Keywords

California , United States , Netherlands , San Carlos , Matt Crenson , Nancy Pryer , Scott Clarke , Melissa Mccracken , Michelle Arkin , Kostenloser Wertpapierhandel , Adam Rosenberg , Christian Ottmann , Luc Brunsveld , Director Of The Small Molecule Discovery Center , Eindhoven University Of Technology , Mission Biocapital , Ventures Fund , Droia Ventures , Inkef Capital , Abbvie Ventures , Surveyor Capital , Pharmaceutical Chemistry , Small Molecule Discovery Center , Chemical Biology , Eindhoven University , Associate Professor , Molecular Cell , Structural Biology , Chief Executive Officer Scott Clarke , Tizona Therapeutics , Trishula Therapeutics , Chief Scientific Officer Nancy Pryer , Day One Biopharmaceuticals , Chief Development Officer , Ambagon Therapeutics , Modular Ambagon Drug Discovery Platform , Bridge Communications , Ambagon , Herapeutics , Aunches , Ith , Billion , Series , Advance , Ioneering , Olecular , Blue , Platform , Progress , Pipeline ,